Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kyle Wathen

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Adaptive Design: Results of 2012 Survey on Perception and UseCaroline Claire Morgan, Susan Huyck, Martin Jenkins, et al.
The Oncologist|February 25, 2012
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003Elizabeth Fox, Shreyaskumar Patel, J Kyle Wathen, et al.
Cancer|January 22, 2013
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)Martee L Hensley, J Kyle Wathen, Robert G Maki, et al.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2010
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trialRashmi Chugh, J Kyle Wathen, Shreyaskumar R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical modelRashmi Chugh, J Kyle Wathen, Robert G Maki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]Robert G Maki, J Kyle Wathen, Shreyaskumar R Patel, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Adaptive Design: Results of 2012 Survey on Perception and UseCaroline Claire Morgan, Susan Huyck, Martin Jenkins, et al.
The Oncologist|February 25, 2012
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003Elizabeth Fox, Shreyaskumar Patel, J Kyle Wathen, et al.
Cancer|January 22, 2013
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)Martee L Hensley, J Kyle Wathen, Robert G Maki, et al.
JAMA Network Open|July 12, 2022
Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional TrialsJay J H Park, Behnam Sharif, Ofir Harari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2010
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trialRashmi Chugh, J Kyle Wathen, Shreyaskumar R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical modelRashmi Chugh, J Kyle Wathen, Robert G Maki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]Robert G Maki, J Kyle Wathen, Shreyaskumar R Patel, et al.
Cancer|December 29, 2015
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcomaScott M Schuetze, J Kyle Wathen, David R Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studySimrit Parmar, Borje S Andersson, Daniel Couriel, et al.
Pageof 2